Loading data for ONC — first visit, this takes a few seconds.

BeOne Medicines AG (ONC)

NasdaqGS: ONC · Real-Time Price · USD

358.26

-4.42 (-1.22%)

At close: Sep 04, 2026, 8:00 PM

358.26

+0.00%

After-hours: 7:30 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	346.74
Market Cap	40.5B
Revenue (ttm)	6.13B
Net Income (ttm)	656M
	0.52
	5.59
	64.09
	34.84
P/B (ttm)	7.83
P/S (ttm)	6.61
Earnings Date	Nov 5, 2026

Ask	358.32
Volume	202,358
Avg. Volume (20D)	361,682
Open	359.71
Previous Close	362.68
Day's Range	357.58 - 362.67
52-Week Range	253.95 - 385.22
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About ONC

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVA...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 3, 2016

Employees 12,000

Stock Exchange NasdaqGS

Ticker Symbol ONC

Website https://beonemedicines.com

Full Company Profile

Financial Performance

In 2025, BeOne Medicines's revenue was 5.34B, an increase of 40.23% compared to the previous year's 3.81B. Earnings were 286.93M, a decrease of -144.5%.

Financial Statements

Earnings Surprise

BeOne Medicines has released their quarterly earnings on Aug 5, 2026:

Revenue of $1.71B misses estimates by $0, with 29.63% YoY growth.
EPS of 2.05 exceeds estimates by 0.42, with 144.05% YoY growth.

Next Earnings Release

BeOne Medicines AG is scheduled to release its earnings on Nov 5, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

6 days ago · Insider Monkey

FDA Approval Marks A Turning Point For BeOne Medicines (ONC)

On August 25, BeOne Medicines (NASDAQ:ONC) said the FDA approved TEVIMBRA in combination with ZIIHERA and chemotherapy as a first-line treatment for HER2-positive gastroesophageal adenocarcinoma, a ha...

1 week ago · Zacks

BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?

Does BeOne Medicines Ltd. - Sponsored ADR (ONC) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 week ago · Zacks

BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?

Is it a good or bad thing when a stock experiences a golden cross technical event?

3 weeks ago · Insider Monkey

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the Augus...

3 weeks ago · GuruFocus.com

BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...

BeOne Medicines Ltd (ONC) delivers robust Q2 2026 results with record BRUKINSA sales, raises full-year guidance, and advances a promising oncology pipeline.

Page 1 of 2

BeOne Medicines AG (ONC)